![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
DB108 is a recombinant protein drug that inhibits tumor growth and metastasis by inhibiting angiogenesis. Denovo gains global rights (except China) to develop, manufacture and commercialize endostatin from Jiangsu Wuzhong Pharmaceutical Group Corporation.
Lead Product(s): Endostatin
Therapeutic Area: Oncology Product Name: DB108
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Denovo Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 10, 2020